Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: DiaSorin, Invitae, Great Basin, Clearbridge BioMedics

NEW YORK (360Dx) – DiaSorin this week completed its acquisition of Siemens Healthineer's microtiter-based ELISA immunodiagnostic business portfolio and related assets. The deal was originally announced in July. The deal does not include the transfer of employees or the manufacturing facility and capability, DiaSorin said. Siemens will continue to manufacture and exclusively provide its ELISA immunodiagnostic reagent kits to DiaSorin for up to three years.

Invitae said that it has commenced an offer to exchange each outstanding Series F warrant to acquire one share of common stock of CombiMatrix for 0.3056 of a share of common stock of Invitae.

The exchange offer will expire at 12:00 a.m., EDT, on Nov. 13.

In July, Invitae announced that it would acquire CombiMatrix as well as Good Start Genetics, which would enable it to add reproductive health testing to its portfolio and fulfill its aim to become a comprehensive genomic information company.

In a filing with the US Securities and Exchange Commission this week, Great Basin Scientific disclosed that it had received notice on Sept. 29 from the OTC Markets Group that due to the company's ongoing delinquency in the filing of its Form 10-Q, it would be moved from the OTCQB market to OTC Pink market. The company earlier disclosed in its Form 8-K that it would not be able to file its Form 10-Q by the Sept. 28 deadline to remain eligible for trading on the OTCQB market.

Clearbridge BioMedics announced this week that it has joined the CANCER-ID public-private international consortium on blood-based biomarkers. CANCER-ID currently has 38 partners from 14 countries. The company is the consortium’s first partner headquartered in Asia. Clearbridge BioMedics has developed the proprietary ClearCell FX System, which is a label-free, enrichment and isolation platform that retrieves intact, viable CTCs from a patient's blood sample. The technology enables processing of both CTCs and ctDNA from the same patient blood sample for subsequent analysis.

The European Commission approved the acquisition of Ambry Genetics by Konica Minolta. The $1 billion deal was announced in July. Upon its completion, Ambry will become a subsidiary of Konica Minolta, which plans to bring the genetic testing firm's technology to Japan and then to Europe. The deal had been expected to close in the third quarter. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.